SCHEMBL4949034

SCHEMBL4949034

CCOC(=O)c1n[nH]c2c1CN(Cc1ccccc1)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 2/20 0.53
ADORA1 P30542 1/20 0.53
ABCB1 P08183 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
ACHE P22303 2/20 0.45
PRMT1 Q99873 1/20 0.44
AKR1B1 P15121 1/20 0.44
CYP19A1 P11511 1/20 0.44
NPC1 O15118 1/20 0.44
TNF P01375 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4944611 0.90 KDM4E (0.47) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL4946012 0.85 ACHE (0.51) KMT2AADORA1ACHEAKR1B1SLC6A5
SCHEMBL25967025 0.81 CCNA2 (0.44) LMNAMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL3391569 0.78 ACHE (0.49) MEN1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL17870553 0.78 CREBBP (0.53) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL25343974 0.77 RBP4 (0.44) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL13373961 0.76 CREBBP (0.53) MAPK1
Hydrochloric Acid SCHEMBL11552823 0.75 LMNA (0.59) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL29371126 0.75 LMNA (0.61) MEN1KMT2ALMNAMAPTADORA1
SCHEMBL20300563 0.74 MEN1 (0.57) MEN1KMT2ALMNAMAPTADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119241539-A Pyrazolo piperidine (ketone) -containing derivative, and preparation method and application thereof 沈阳药科大学 2025-01-03 CN disclosed
EP-1885725-B1 TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2008-09-24 EP disclosed
EP-1885725-A1 TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-02-13 EP disclosed
WO-2006108488-A1 TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 WO disclosed
US-20060235013-A1 Tricyclic azole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235013-A1 Tricyclic azole derivatives CYP3A5, CYP3A43, CYP11B1 MEN1 516/4885KMT2A 2810/4885LMNA 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.